ELVN
Enliven Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$49.45
−1.57%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$49.62
From 52W high−19.13%
Volume5.92M
Market cap$3.62B
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataSep 18, 2026
Open
$49.62
From 52W high
−19.13%
Volume
5.92M
Market cap
$3.62B
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−25.8x
P/E (TTM)
—
RSI (14)
28.5
MomentumView details →
1D Return
−1.57%
YTD Return
+221.79%
SummaryUpdated Jun 1, 2026
Enliven Therapeutics, Inc. (NASDAQ:ELVN) is a clinical-stage biopharmaceutical company founded in 2020 and based in Boulder, Colorado. The company went public on March 12, 2020, and focuses on discovering and developing small molecule inhibitors designed to treat various forms of cancer. As a clinical-stage biotech company, Enliven is currently advancing multiple drug candidates through early-phase clinical trials, with no approved products or revenue to date.
Similar companies
Latest newsMore news →
Enliven Therapeutics closed an upsized underwritten public offering of common stock and pre-funded warrants, including full exercise of the underwriters' option to purchase additional shares.97d agoEnliven Therapeutics commenced an underwritten public offering of $250.0 million of shares of its common stock and pre-funded warrants.101d ago